REVB

Revelation Biosciences Inc. (REVB) | Rumor.io

Revelation Biosciences

REVB

Attention (50-day avg)0%

Attention rank (50-day avg)#4,223

Bullish sentiment (50-day avg)67%

Price to earnings ratio0.03

Market capitalization3.4M

Earnings per share27

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8.9M

Social

What share of all stock conversation is about REVB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 30

$REVB is considered undervalued with a potential price of $5 per share.
Revelation Biosciences, Inc. has presented additional positive data from a prime clinical study, which may lead to a price increase.
$REVB is seen as a low-risk, high-reward investment opportunity, with some analysts expecting a significant price move.

Generated by AI

Sentiment

Of the messages about REVB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	81.02% -0.54
Bearish	—	—	—	18.98% +0.54

Bullish· Mar 30

REVB has the potential for a big move, with preclinical study results suggesting a significant opportunity for growth.
The company's cash reserve of $5 per share and warrants at $3.45 make it a low-risk, high-reward investment.
REVB is poised for a reversal, with its price currently trading at 52-week lows and showing signs of momentum as volume continues to rise.

Bearish· Mar 30

$REVB is considered oversold and undervalued, with some investors believing it is due for a significant price increase.
The stock has a low float, which could lead to large price movements in a short amount of time.
The price of $REVB is seen as being heavily discounted, with some investors expecting it to increase to $5 or more per share.

Generated by AI

Topics

Of the messages about REVB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	47.81%
Analysts	—	—	—	2.69%
Controversies	—	—	—	0%
Earnings	—	—	—	0.34%
Macro	—	—	—	19.53%
Technical Analysis	—	—	—	29.63%

Announcements· Sep 10

Revelation Biosciences announced a special webcast to review positive top-line clinical data from its Phase 1b trial for Gemini in stage 3 and 4 CKD patients.
The trial met its primary endpoint, evaluating the safety and tolerability of escalating doses of Gemini, and showed restored immune responsiveness in patients.
Revelation Biosciences' market capitalization is under $5 million, and the company's stock price surged 41% premarket following the announcement.

Technical Analysis· Jan 23

$REVB is holding firm at current levels with buyers stepping in on dips, indicating real demand.
A potential reversal zone has been identified at the current price level, with some traders looking to buy and hold into next week.
$REVB needs to break the downtrend and the VWAP to confirm a potential breakout, and increased volume is required to achieve this.

Generated by AI

Community

Of the messages about REVB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	29.32%
Newcomers	—	—	0%	70.68%

Regulars· Jan 23

A signal from the Oracle Algo scanner resulted in a 30.6% gain for $REVB when it climbed to $1.45.
Revelation Biosciences, Inc. exercised warrants for $11 million in gross proceeds.
$REVB needs increased volume to break the downtrend and the VWAP.

Newcomers· Jan 26

Revelation Biosciences, Inc. (REVB) is facing its third reverse split in a year, causing a 10% drop in stock value.
New investors are buying shares of REVB, with some mentioning the company in their posts and others seeking to connect with other investors.
Some analysts are looking at REVB's revenue, with one noting a 253% YoY increase in December revenue to $8.01M, and another mentioning a potential price target of $5.

Generated by AI

News

Revelation Biosciences grants restricted stock awards to CEO and CFO

1mo agoInvesting.com

Revelation Biosciences selects CRO for phase 2/3 AKI study

1mo agoInvesting.com

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

SAN DIEGO, August 19, 2026--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI).

1mo agoYahoo Finance

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported ...

1mo agoYahoo Finance

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today ...

1mo agoYahoo Finance

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced ...

2mo agoYahoo Finance

Also Discussed

Investors talking about REVB also mention

#	Name	Attention
1	Avenue Therapeutics Inc.ATXI	0%new
2	UOKA - MDJM Ltd	——
3	Golden Heaven Group Holdings Ltd.GDHG	0%0
4	AREB - American Rebel Holdings, Inc.	——
5	SMFL - Smart for Life, Inc.	——
6	Brenmiller Energy LtdBNRG	0%new
7	CMAX - CareMax, Inc.	——
8	TransCode Therapeutics, Inc.RNAZ	0%+0
9	Dermata Therapeutics, Inc.DRMA	0%new
10	Ensysce Biosciences, Inc. Common StockENSC	0%0

Revelation Biosciences Inc.

Healthcare
Biotechnology

Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing immunologic therapies and diagnostics that modulate the innate immune system. Its current pipeline centers on product candidates designed to address inflammatory and infectious disease settings, including treatments for allergic rhinitis and chronic nasal congestion, rapid home-use diagnostics for respiratory viral infections, and intranasal immunomodulator approaches used alongside vaccination. The company also works on therapeutic programs targeting acute kidney injury, chronic kidney disease, and other conditions linked to dysregulated inflammation. Revelation Biosciences Inc. develops products intended for use in prevention and treatment across hospital, outpatient, and at-home care settings, with a focus on clinically relevant immune-response modulation. Based in San Diego, California, the company operates in the biotechnology sector and maintains a narrow, research-driven portfolio aimed at immune system therapeutics and diagnostics.

Website

Location

4660 La Jolla Village Drive

San Diego, CA, 92122

United States

Social

What share of all stock conversation is about REVB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 30

$REVB is considered undervalued with a potential price of $5 per share.
Revelation Biosciences, Inc. has presented additional positive data from a prime clinical study, which may lead to a price increase.
$REVB is seen as a low-risk, high-reward investment opportunity, with some analysts expecting a significant price move.

Generated by AI

Sentiment

Of the messages about REVB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	81.02% -0.54
Bearish	—	—	—	18.98% +0.54

Bullish· Mar 30

REVB has the potential for a big move, with preclinical study results suggesting a significant opportunity for growth.
The company's cash reserve of $5 per share and warrants at $3.45 make it a low-risk, high-reward investment.
REVB is poised for a reversal, with its price currently trading at 52-week lows and showing signs of momentum as volume continues to rise.

Bearish· Mar 30

$REVB is considered oversold and undervalued, with some investors believing it is due for a significant price increase.
The stock has a low float, which could lead to large price movements in a short amount of time.
The price of $REVB is seen as being heavily discounted, with some investors expecting it to increase to $5 or more per share.

Generated by AI

Topics

Of the messages about REVB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	47.81%
Analysts	—	—	—	2.69%
Controversies	—	—	—	0%
Earnings	—	—	—	0.34%
Macro	—	—	—	19.53%
Technical Analysis	—	—	—	29.63%

Announcements· Sep 10

Revelation Biosciences announced a special webcast to review positive top-line clinical data from its Phase 1b trial for Gemini in stage 3 and 4 CKD patients.
The trial met its primary endpoint, evaluating the safety and tolerability of escalating doses of Gemini, and showed restored immune responsiveness in patients.
Revelation Biosciences' market capitalization is under $5 million, and the company's stock price surged 41% premarket following the announcement.

Technical Analysis· Jan 23

$REVB is holding firm at current levels with buyers stepping in on dips, indicating real demand.
A potential reversal zone has been identified at the current price level, with some traders looking to buy and hold into next week.
$REVB needs to break the downtrend and the VWAP to confirm a potential breakout, and increased volume is required to achieve this.

Generated by AI

Community

Of the messages about REVB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	29.32%
Newcomers	—	—	0%	70.68%

Regulars· Jan 23

A signal from the Oracle Algo scanner resulted in a 30.6% gain for $REVB when it climbed to $1.45.
Revelation Biosciences, Inc. exercised warrants for $11 million in gross proceeds.
$REVB needs increased volume to break the downtrend and the VWAP.

Newcomers· Jan 26

Revelation Biosciences, Inc. (REVB) is facing its third reverse split in a year, causing a 10% drop in stock value.
New investors are buying shares of REVB, with some mentioning the company in their posts and others seeking to connect with other investors.
Some analysts are looking at REVB's revenue, with one noting a 253% YoY increase in December revenue to $8.01M, and another mentioning a potential price target of $5.

Generated by AI

Revelation Biosciences

Social

Mar 30

Bullish· Mar 30

Bearish· Mar 30

Announcements· Sep 10

Technical Analysis· Jan 23

Regulars· Jan 23

Newcomers· Jan 26

Revelation Biosciences grants restricted stock awards to CEO and CFO

Revelation Biosciences selects CRO for phase 2/3 AKI study

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Revelation Biosciences Inc.

Company Information

Location

Revelation Biosciences grants restricted stock awards to CEO and CFO

Revelation Biosciences selects CRO for phase 2/3 AKI study

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Social

Mar 30

Bullish· Mar 30

Bearish· Mar 30

Announcements· Sep 10

Technical Analysis· Jan 23

Regulars· Jan 23

Newcomers· Jan 26